FOLFOX4: clear benefit in colorectal cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1347, 2002-01, pp. : 13-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

XELOX dominant over FOLFOX4 for colorectal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 585, 2009-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Removing oxaliplatin from FOLFOX feasible in colorectal cancer

By  

Inpharma, Vol. 1, Iss. 1528, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

FOLFOX-4 most effective, expensive in colon cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 594, 2010-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer

By Madajewicz Stefan  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 772-778

Springer Publishing Company

Access to resources Recommend Favorite

FOLFOX4 feasible first-line therapy for advanced gastric cancer

By  

Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite